Prevalence and prognostic value of zinc and selenium deficiency in advanced chronic liver disease

Summary Background and Aims Zinc and selenium are essential trace elements involved in important (patho)physiological processes. The prevalence and prognostic implications of zinc and selenium deficiency in patients with advanced chronic liver disease (ACLD) remain unknown. Methods We determined serum zinc and selenium concentrations in 309 patients with ACLD undergoing hepatic venous pressure gradient (HVPG) measurement between 2019 and 2022. We evaluated the prevalence of zinc/selenium deficiency and assessed its association with severity of ACLD and liver‐related events (LRE, i.e. first/further hepatic decompensation/liver‐related death). Results Among 309 ACLD patients (median: age: 57 [IQR: 50–64], MELD: 11 [IQR: 9–16], HVPG: 17 [IQR: 11–20]), 73% (227) and 63% (195) were deficient in zinc and selenium, respectively. Decompensated (dACLD) patients showed significantly lower serum zinc (median: 48 [IQR: 38–59] vs. compensated, cACLD: 65 [IQR: 54–78], p < 0.001) and selenium levels (median: 4.9 [IQR 4.0–6.2] vs. cACLD: 6.1 [IQR 5.1–7.3], p < 0.001). Significant correlations of zinc/selenium levels were found with MELD (zinc: ρ = −0.498, p < 0.001; selenium: ρ = −0.295, p < 0.001), HVPG (zinc: ρ = −0.400, p < 0.001; selenium: ρ = −0.157, p = 0.006) and liver disease‐driving mechanisms (IL6, bile‐acid homeostasis). On multivariable analysis, low zinc/selenium levels, age and MELD remained independently associated with LRE. Conclusion Zinc and selenium deficiencies are common in ACLD patients especially with higher MELD and HVPG. Low zinc and selenium levels independently predicted hepatic decompensation and liver‐related death. The effect of zinc/selenium supplementation in ACLD should be investigated in future trials.